In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antisoma Takes Refuge With Roche

Executive Summary

Roche could easily have swallowed cash-poor Antisoma whole. But the Swiss group has instead bought rights to the UK biotech's entire clinical portfolio, hoping thereby to preserve Antisoma's creativity--rather like it has done with Genentech.

Related Content

Five-Year GSK/NeuroSearch Alliance: Big On Guarantees
Roche's Partners: Replacing, or Fuelling In-House R&D?
Roche Signs Up Ipsen--Again
Cancer Research Technology Ltd.
Roche Boosts Beaufour
Biotechs on the Brink Choose Last-Minute Deals, Not Liquidation
Roche Bucks the Trend, with Early-Stage Deals
UK Biotech Learns the Hard Way
Roche/Chugai Blaze a Trail...But Will Anyone Follow?


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts